Kieran O'Kane - May 8, 2024 Form 4 Insider Report for BIODESIX INC (BDSX)

Role
Chief Commercial Officer
Signature
/s/ Robin H. Cowie as Attorney-in-Fact for Kieran O'Kane
Stock symbol
BDSX
Transactions as of
May 8, 2024
Transactions value $
-$692
Form type
4
Date filed
5/10/2024, 05:05 PM
Previous filing
Apr 9, 2024
Next filing
May 23, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BDSX Common Stock Options Exercise +1.49K +2% 76K May 8, 2024 Direct F1, F2, F3
transaction BDSX Common Stock Sale -$692 -468 -0.62% $1.48 75.5K May 9, 2024 Direct F4, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BDSX Restricted Stock Units Options Exercise $0 -1.49K -12.5% $0.00 10.4K May 8, 2024 Common Stock 1.49K Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2 Includes an aggregate 59 shares that were inadvertently reported as being sold on February 9 and February 12, 2024 in the Form 4 filed by the Reporting Person on February 12, 2024.
F3 Includes 6,439 shares purchased under the Issuer's Employee Stock Purchase Plan on February 29, 2024.
F4 These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.
F5 The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.43 to $1.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.